Our study revealed that IDO1 is essential for the proliferation of DLBCL cells and that it may be a potential therapeutic target and provide new insight to develop a promising strategy by combining IDO1 with conventional therapies for the treatment of DLBCL. This evidence concerns the gene IDO1 and diffuse large B-cell lymphoma.